Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Drug-Drug Interaction, Safety and Efficacy Study With JNJ-56021927 (ARN-509) and Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer

NCT02123758 is registered in ClinicalTrials.gov with Aragon Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02123758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02123758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Drug-Drug Interaction, Safety and Efficacy Study With JNJ-56021927 (ARN-509) and Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
Aragon Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 9, 2014
Completion date
December 31, 2027
Enrollment
57 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer, prostatic neoplasms